Related Experiment Video
Updated: May 1, 2026
19:15
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
90.5K
Teratogenic mechanisms associated with prenatal medication exposure
Marleen M H J van Gelder1, Iris A L M van Rooij1, Lolkje T W de Jong-van den Berg2
1Department for Health EvidenceRadboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Therapie
|April 5, 2014
Summary
Medications during early pregnancy can cause birth defects through six main teratogenic mechanisms. Combining therapies may significantly increase risks for pregnant women.
Area of Science:
- Developmental toxicology
- Reproductive medicine
- Pharmacology
Background:
- Birth defects can arise from various exposures, notably medications taken during early pregnancy.
- Understanding teratogenic mechanisms is crucial for preventing congenital anomalies.
Purpose of the Study:
- To review the six principal teratogenic mechanisms associated with medication use in pregnancy.
- To highlight the implications of these mechanisms for research and clinical practice.
Main Methods:
- Literature review of teratogenic mechanisms.
- Synthesis of evidence from animal models and human studies.
- Analysis of the impact of multi-therapy on teratogenic risk.
Main Results:
- Identified six key teratogenic mechanisms: folate antagonism, neural crest cell disruption, endocrine disruption, oxidative stress, vascular disruption, and receptor/enzyme-mediated teratogenesis.
- Evidence for some mechanisms is primarily from animal models.
- Combined medication use may amplify teratogenic effects through shared pathways.
Conclusions:
- Knowledge of teratogenic mechanisms informs etiological and post-marketing surveillance.
- Findings have implications for prescribing practices for women of reproductive age.
- Multi-therapy poses a significantly increased risk for birth defects due to potential synergistic teratogenic mechanisms.
Related Concept Videos
01:07Teratogenicity
4.2K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.2K
01:24Drug Toxicity: Dose-Dependent Reactions
229
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
229
01:24Drug Toxicity: Risk factors
229
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
229
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
01:30Drug toxicity: Drug–Drug Interaction
423
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
423
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
410
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410